• Janux Therapeutics announced in January 2026 that it had entered a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated solid-tumor therapy, potentially worth up to US$850 million in upfront, near-term, and milestone payments plus tiered royalties.
• In parallel, Bristol Myers Squibb’s recent AI-focused partnership with Microsoft on early lung cancer detection highlights how the company is pairing oncology drug development with digital health tools to broaden its role across the cancer care continuum.
• We’ll now examine how Bristol Myers Squibb’s push into AI-enabled lung cancer detection with Microsoft could reshape its investment narrative.

Outshine the giants: these 24 early-stage AI stocks could fund your retirement.

What Is Bristol-Myers Squibb's Investment Narrative?

For Bristol Myers Squibb to make sense in a portfolio, you need to believe that its established oncology and cardiovascular franchises, together with a deep pipeline, can offset expected top line pressure and patent headwinds over the next few years. The stock still trades at what looks like a discount to both analyst targets and some valuation models, with a high, long-running dividend as part of the appeal, but revenue is forecast to decline and growth expectations are modest. Against that backdrop, the Janux deal and the Microsoft AI lung cancer partnership feel more like incremental, longer-term story builders than near-term catalysts, so they may not move the needle on the upcoming earnings reset, high debt load, or pricing risk just yet.

However, investors should pay close attention to how the high debt and slowing revenue trend evolve. Bristol-Myers Squibb's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

The 12 fair value estimates from the Simply Wall St Community span roughly US$48 to about US$134.37 per share, reflecting very different expectations. Set against concerns about forecast revenue declines and a heavy debt burden, this wide spread underlines how differently people are thinking about Bristol Myers Squibb’s ability to convert its partnerships and pipeline into sustained performance, inviting you to weigh several perspectives before forming your own view.

Explore 12 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth 13% less than the current price!

Build Your Own Bristol-Myers Squibb Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.